



## Interface Prescribing & New Therapies Subgroup



December 2012

### **Mirabegron (Betmiga®▼) for the treatment of overactive bladder**

**The Interface Prescribing and New Therapies Subgroup discussed the above drug at its meeting on the 18<sup>th</sup> December 2012. The recommendation of this subgroup is as follows:\***

The Interface Prescribing & New Therapies Subgroup of the GMMMG considered the use of Mirabegron for the treatment of overactive bladder.

**The group does not recommend the prescribing of Mirabegron pending the NICE technology appraisal which is due in June 2013.**

Mirabegron has shown significant improvements in a number of OAB measures, however, it is unclear as to whether it offers a superior treatment option to currently available treatments.

Whilst it may offer a different side effect profile to antimuscarinic agents, this doesn't mean it is without side effects itself.

Mirabegron is associated with an increase in blood pressure and lacks the long-term safety data available with more established treatment options, which also offer more cost-effective treatment options.

According to set criteria Mirabegron was deemed to be a low priority for funding.

Review date: September 2013

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm their risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.